VISTAR HOLDINGS (08535) issues profit warning, expects interim net loss of approximately HK$480,000
VISTAR HOLDINGS (08535) announced that the Group is expected to record a net loss of approximately HK$480,000 for the six months ended September 30, 2026, compared with a net profit of approximately HK$410,000 for the six months ended September 30, 2025.
VISTAR HOLDINGS (08535) announces that the Group is expected to record a net loss of approximately HK$480,000 for the six months ended 30 September 2026, compared with a net profit of approximately HK$410,000 for the six months ended 30 September 2025. The expected turnaround from profit to loss is primarily due to a decrease in gross profit resulting from lower revenue, despite an increase in the Group's overall gross profit margin. The decrease in installation engineering revenue reflects fewer newly awarded installation projects, coupled with original installation projects gradually approaching completion while new installation projects remain at an early stage. Projects at these stages involve lower construction volume, and therefore less revenue was recognized during the reporting period. The Group's other income and gains, as well as the net reversal of impairment losses on trade receivables and contract assets, also decreased. The above adverse effects were partially offset by decreases in administrative and other operating expenses and finance costs.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process

Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares

CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%
Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process

Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares

CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%






